The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Agenus; Amgen; Johnson & Johnson; MacroGenics; MSD; Pfizer; Roche; Ryvu Therapeutics
Consulting or Advisory Role - Roche
Research Funding - Agenus
Travel, Accommodations, Expenses - Novartis; Roche
Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: Results of the expanded cohort of myxoid liposarcoma of the randomized clinical trial from the Italian Sarcoma Group (ISG), the Spanish Sarcoma Group (GEIS), the French Sarcoma Group (FSG), and the Polish Sarcoma Group (PSG).
 
Alessandro Gronchi
Honoraria - Deciphera; Lilly; Novartis; Pfizer; PharmaMar
Consulting or Advisory Role - Bayer; Lilly; Nanobiotix; Novartis; Pfizer; PharmaMar; SpringWorks Therapeutics
Research Funding - Nanobiotix (Inst); PharmaMar (Inst)
Travel, Accommodations, Expenses - Nanobiotix; PharmaMar
 
Emanuela Palmerini
Honoraria - Amgen
Consulting or Advisory Role - Amgen; Daiichi Sankyo; Deciphera; EUSA Pharma; Lilly; SynOX
Research Funding - Daiichi Sankyo; PharmaMar (Inst)
Travel, Accommodations, Expenses - Amgen; Daiichi Sankyo; Lilly; Takeda
 
Vittorio Quagliuolo
No Relationships to Disclose
 
Javier Martin Broto
Honoraria - Bayer; Eisai; GlaxoSmithKline; Lilly; Novartis; PharmaMar; Tecnofarma
Consulting or Advisory Role - Amgen; Asofarma; Bayer; GlaxoSmithKline; Lilly; Novartis; PharmaMar; Roche; Tecnofarma
Speakers' Bureau - PharmaMar
Research Funding - Amgen (Inst); Bayer (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Eisai; Eisai (Inst); FORMA Therapeutics (Inst); GlaxoSmithKline (Inst); Immix BioPharma (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Lixte Biotechnology (Inst); Nektar (Inst); Novartis; Novartis (Inst); Pfizer (Inst); PharmaMar
Expert Testimony - Novartis; PharmaMar
Travel, Accommodations, Expenses - Pfizer; PharmaMar
 
Antonio Lopez-Pousa
No Relationships to Disclose
 
Giovanni Grignani
Honoraria - Bayer; Eisai; GlaxoSmithKline; Lilly; Merck Serono; Novartis; Pfizer; Pfizer; PharmaMar
Consulting or Advisory Role - Bayer; Eisai; GlaxoSmithKline; Merck; PharmaMar
Speakers' Bureau - GlaxoSmithKline; GlaxoSmithKline
Research Funding - PharmaMar (Inst)
Travel, Accommodations, Expenses - PharmaMar; tesaro
 
Antonella Brunello
Consulting or Advisory Role - Eisai; GlaxoSmithKline; PharmaMar
Travel, Accommodations, Expenses - PharmaMar; Takeda
 
Jean-Yves Blay
Leadership - Innate Pharma
Honoraria - AstraZeneca; Bayer; BMS; Deciphera; Ignyta; MSD; PharmaMar; Roche
Consulting or Advisory Role - Bayer; Blueprint Medicines; Deciphera; Deciphera; Deciphera; Deciphera; Karyopharm Therapeutics; Pharmamar; Roche
Research Funding - AstraZeneca (Inst); Bayer (Inst); BMS (Inst); DEciphera (Inst); GlaxoSmithKline (Inst); MSD (Inst); Novartis (Inst); OSE Pharma (Inst); Pharmamar (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Roche
 
Robert Diaz Beveridge
No Relationships to Disclose
 
Virginia Ferraresi
No Relationships to Disclose
 
Iwona Lugowska
No Relationships to Disclose
 
Sara Pizzamiglio
No Relationships to Disclose
 
Paolo Verderio
No Relationships to Disclose
 
Valeria Fontana
No Relationships to Disclose
 
Davide Maria Donati
No Relationships to Disclose
 
Elena Palassini
Research Funding - Advenchen Laboratories (Inst); Amgen/Dompé (Inst); Bayer (Inst); Daiichi Sankyo (Inst); Epizyme (Inst); GlaxoSmithKline (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); SpringWorks Therapeutics (Inst)
 
Silvia Stacchiotti
Honoraria - Aadi; GlaxoSmithKline; PharmaMar
Consulting or Advisory Role - Astex Pharmaceuticals; Bavarian Nordic; Bayer; Daiichi Sankyo; Deciphera; Epizyme; GlaxoSmithKline; Ikena Oncology; MaxiVax; Novartis; PharmaMar; Rain Therapeutics
Research Funding - Advenchen Laboratories (Inst); Amgen (Inst); Bayer (Inst); Blueprint Medicines (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Epizyme (Inst); GlaxoSmithKline (Inst); Hutchison MediPharma (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); SpringWorks Therapeutics (Inst)
Travel, Accommodations, Expenses - PharmaMar
 
Rosalba Miceli
No Relationships to Disclose
 
Angelo Paolo Dei Tos
No Relationships to Disclose
 
Paolo Giovanni Casali
Research Funding - Advenchen Laboratories (Inst); Amgen/Dompé (Inst); Arog (Inst); Bayer (Inst); Blueprint Medicines (Inst); Daiihi Sankyo (Inst); Deciphera (Inst); Eisai (Inst); Epizyme (Inst); GlaxoSmithKline (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst)